Edition:
United Kingdom

People: Aptose Biosciences Inc (APTO.OQ)

APTO.OQ on NASDAQ Stock Exchange Capital Market

2.01USD
13 Nov 2018
Change (% chg)

$-0.07 (-3.37%)
Prev Close
$2.08
Open
$2.10
Day's High
$2.11
Day's Low
$1.99
Volume
52,138
Avg. Vol
33,896
52-wk High
$4.55
52-wk Low
$1.68

Ashe, Carol 

Ms. Carol Ashe is Director of the Company. Ms. Ashe is an accomplished executive leader with more than 25 years of experience in corporate, legal, business development and venture capital in the pharmaceutical and biotech industries. In this capacity, she has a depth and breadth of transactional expertise in negotiating and structuring transactions involving academic institutions and biotech and pharmaceutical companies of all stages, including acquisitions, joint venture agreements, R&D collaborations and in-license agreements, among others. She currently serves as Chief Business Officer of the NY Genome Center, where she is responsible for identifying and executing on revenue generating business development opportunities. As Vice President of Corporate Development for the pharmaceutical segment of Endo, Ms. Ashe led the evaluation, structuring and negotiation of business development transactions for Endo's branded, generic and platform drug delivery business units. Prior to that, she was a Partner at GlaxoSmithKline's corporate venture capital fund SR One, evaluating early-stage through Phase II investment opportunities in life science companies and serving as a Board observer for a select group of portfolio companies. Ms. Ashe led GSK's US Corporate Legal Group, which supported US M&A transactions, as well as its Business Development Legal Transactions team, which supported business development transactions across all of GSK's business units on a global basis. She received her bachelor's degree in Biology at Pennsylvania State University and a law degree from the Villanova University School of Law.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --